Is RAD 140 a steroid? No. It is a selective androgen receptor modulator (SARM), a nonsteroidal compound built on a chemical core other than the four-ring steroid skeleton. It shares its target with testosterone and the steroids derived from it: the compound, also called testolone, switches on the androgen receptor, the protein androgens act through inside cells.
Chemistry and anti-doping papers agree on the grouping. They place the compound with the nonsteroidal SARMs, built on a core other than the steroid skeleton, and apart from the anabolic-androgenic steroids, the synthetic derivatives of testosterone. A different structure does not mean milder harm: published cases describe drug-induced liver injury and suppression of endogenous testosterone signalling after exposure to products containing RAD 140. The comparisons drawn with Anavar (oxandrolone) and tren (trenbolone), both members of the steroid class, one orally active and the other injectable, rest on descriptions outside the published trials rather than on any trial.
Where does the compound come from? The SARM RAD140 was designed as a potent, orally bioavailable drug candidate in a medicinal chemistry programme that characterised the SARM testolone in preclinical models of anabolic action, the building of skeletal muscle and bone tissue. It entered clinical development under the name vosilasarm, and no regulator has granted it full clinical approval: the record from the discovery programme to vosilasarm is that of a research compound, not of an approved medicine.
This article sets out what the compound is chemically and how it acts at the receptor compared with anabolic-androgenic steroids and with prohormones, precursors that enzymes convert into active steroids; what the published cases and laboratory analyses recorded; and how the compound is described beside Anavar, trenbolone and methandienone (dbol), an orally active 17-alpha-alkylated steroid. Dose plans and UK law have their own pages.
How RAD140’s structure differs from a steroid’s
RAD-140 rests on a 5-phenyloxadiazole nucleus, a ring system unrelated to the four-ring skeleton of testosterone and its derivatives, and that is what places it among the non-steroidal SARMs. Its discovery paper says the same in its own words (a nonsteroidal selective androgen receptor modulator), and the two descriptions agree because of the structural distance from testosterone.
The same structure answers whether RAD 140 is natural. It is synthetic, designed and made in a medicinal chemistry programme, and anti-doping chemists later prepared reference material for it by established synthetic routes so that they could characterise its mass-spectrometric behaviour; its origin lies in the laboratory, not in a plant or in animal tissue.
Steroidal and nonsteroidal SARMs named in sources
Compound
Steroid skeleton
Core named in the sources
Source
RAD-140
No
5-phenyloxadiazole nucleus
ACP-105
No
N-substituted tropanol pharmacophore
LGD-4033 (ligandrol)
No
Not named
Ostarine (enobosarm)
No
Not named
MK-0773
Yes
Steroidal SARM
YK-11
Yes
Steroidal SARM
The SARM class is chemically mixed, so the label alone decides little: what unites selective androgen receptor modulators is the receptor pharmacology they share despite that variety. A doping-control review lists RAD-140 among the nonsteroidal representatives and names MK-0773 and YK-11 as steroidal SARMs, members of the class that keep a steroid skeleton; calling a compound a SARM therefore says nothing about its skeleton, and on that division RAD-140 falls on the nonsteroidal side.
The grouping has shaped how the compound’s breakdown has been studied. One study examined RAD-140 alongside six other non-steroidal SARMs in equine liver microsomes, and for RAD-140 it identified four metabolites, the compounds a drug is broken down into.
How do prohormones differ from SARMs like RAD140?
In the comparison of SARMs vs prohormones, the first difference is the route: a prohormone becomes an active steroid only after enzymes convert it in the body, while RAD140 needs no such step. The second is the range of tissues acted on. The differences, and the qualification that narrows them, run along five points, each as it is commonly described:
Route: a prohormone is generally held to be a precursor that enzymes convert in vivo into one of the active anabolic-androgenic steroids, whereas RAD140 is widely understood to act directly on the androgen receptor.
Class: that difference in route is why prohormones are commonly classed with the anabolic-androgenic steroids, while a non-steroidal selective androgen receptor modulator is not.
Range of tissues: steroids formed from a prohormone are commonly described as acting on androgen receptors in tissues throughout the body, whereas RAD140 is described in preclinical work as favouring skeletal muscle and bone tissue over prostate tissue.
Onward conversion: those steroids are commonly described as open to conversion into dihydrotestosterone or into oestrogen, the sex steroid formed from androgens by aromatase, whereas RAD140 is not converted into a steroid hormone at all.
Shared qualification: that tissue preference is usually qualified as only partial tissue selectivity, the uneven effect of one compound across different tissues, because suppression of endogenous testosterone production and published descriptions of drug-induced liver injury attach to RAD140 as they do to orally active steroids.
How RAD140 acts on the androgen receptor compared with steroids
RAD140 acts on the same androgen receptor as testosterone and the anabolic-androgenic steroids, and in preclinical work it is anabolic: its discovery paper settled whether RAD 140 is anabolic by characterising it in preclinical models of anabolic androgen action in rats and monkeys. Receptor binding was reported there as a Ki, or binding constant, lower than the comparator’s, as the chart below shows, and a lower Ki means tighter binding, which is what a nonsteroidal compound acting at the receptor steroids use would be expected to show.
So the difference between SARMs and steroids lies not in the receptor but in the balance between two effects. A forensic review describes SARMs as presenting anabolic properties identical to those of anabolic-androgenic steroids with markedly reduced androgenic effects, and the published liver case describes RAD-140 as potently anabolic on bone and muscle tissue with little androgenic effect. That balance, followed through the receptor, is what separates the two classes.
[Figure 1. RAD140 at the androgen receptor, three readouts. RAD140, built on a nonsteroidal core, binds the same androgen receptor steroids use: anabolic in rat and monkey models, androgenic in a yeast screen and more strongly in prostate carcinoma cells. Preclinical and cellular data only, no human data.]
Selectivity is not absence, and tissue selectivity left RAD-140 with androgenic activity in both a yeast androgen screen, a reporter assay in yeast cells that detects androgenic compounds, and a reporter gene assay in prostate carcinoma cells, markedly stronger in the prostate cells than in the yeast, and molecular modelling of the androgen receptor ligand binding domain found only slight differences in binding mode between RAD-140 and two other non-steroidal SARMs. On these data selectivity is a matter of degree rather than of kind.
The nonsteroidal core did not spare the liver: the best-documented harm in the published cases is RAD 140 liver injury, with a gynaecomastia case and a splenic rupture beside it, all set out in their own articles.
How much does RAD140 shut down testosterone compared with steroids?
One published case of exposure to products containing RAD-140 measured the hormone axis, and in it endogenous testosterone signalling was shut down: a biochemical hypogonadotropic hypogonadism, low testosterone together with low pituitary gonadotropin output. The same products held undisclosed steroid hormones, so the suppression cannot be apportioned between RAD-140 and those hormones.
Commercially available performance-enhancing supplements can contain banned performance-enhancing drugs (PEDs) and undisclosed steroid hormones that can induce hormonal abnormalities with associated clinical signs.
The details set that limit. A 40-year-old man developed bilateral gynaecomastia, enlargement of male breast tissue, alongside the biochemical picture after six months of exposure to three commercially available supplements; analysis found RAD-140, MK-677 and cardarine (a PPAR-delta agonist), and in all three undisclosed testosterone, growth hormone and oestradiol (the principal oestrogen), while liquid chromatography-mass spectrometry, the separation and mass-measurement method used for steroid analysis, detected an unidentified compound coeluting close to the testosterone peak.
Once exposure ended, the symptoms resolved fully and the hypogonadotropic hypogonadism normalised. What the case records is suppression produced by a mixture of a SARM and administered steroid hormones acting on one hypothalamic-pituitary-gonadal axis; to compare its degree with an anabolic-androgenic steroid’s would take RAD-140 administered alone with the hormone axis measured, a design absent from the studies this article draws on.
How does RAD140 compare with anavar for strength, gains and side effects?
Among the effects described outside the trials, the strength and size attributed to RAD140 beside oxandrolone divide sharply: in some accounts oxandrolone does clearly more over a comparable period, in others the two yield much the same strength, hardness and vascularity, with RAD140 said to be nearly as drying, and the descriptions leave open whether RAD140 matches oxandrolone for lean body mass as well as for strength.
Accounts outside the published studies make the blood lipids (the HDL and LDL cholesterol fractions measured in a blood panel) the sharpest divergence on side effects, describing them as worsening far more after exposure to oxandrolone than after RAD140, and oxandrolone as driving cholesterol and liver markers up; in descriptions beyond the trials RAD140’s advantage in side effects is itself questioned, so these competing accounts settle nothing that a measurement would.
Outside the trial record, suppression of endogenous hormones is the point of sharpest disagreement: oxandrolone on its own is said rarely to suppress endogenous testosterone completely, though other accounts question that at higher amounts, and beyond the trial data oxandrolone is placed above the SARM class in potency and below the injectable anabolic-androgenic steroids, an ordering that leaves RAD140 lower still on a rough scale of strength.
Outside the published trials, in descriptions concerning women, oxandrolone predominates and RAD140 appears in only a few; such descriptions come from RAD-140 Reddit and other online accounts, with no figures attached to any of them.
How does RAD140 compare with tren or dbol?
Outside the published trials, RAD140 is described as weaker than trenbolone or methandienone, both spoken of as the stronger agents, so a straight RAD 140 vs tren substitution is rarely the comparison drawn; where the two are compared directly, one account calls the effect on aggression tren-like while holding that it comes without trenbolone’s harsher effects, and other descriptions ask instead how RAD140 stands for strength alone against stanozolol (winstrol), another of the orally active anabolic-androgenic steroids.
In those accounts methandienone enters chiefly through aromatisation, the enzymatic conversion of an androgen into oestrogen: alone it is described as bringing quick fullness and weight that does not hold once exposure ends, and accounts outside the published studies record suspicion that material sold as RAD140 was in fact a prohormone or liquid methandienone.
On the pharmacology rather than the descriptions, RAD140 is generally held to be a different kind of compound from either of the two, not a weaker version of one. Non-steroidal and built to favour skeletal muscle and bone over prostate tissue, it is usually described as having milder androgenic and oestrogenic effects than either, while trenbolone is commonly described as strongly androgenic and non-aromatising and as acting on the progesterone receptor, and methandienone is generally held to convert to oestrogen and is widely linked with strain on liver tissue. The usual qualification stands: RAD140 still suppresses endogenous testosterone production, has been linked with drug-induced liver injury in published cases, and has never been set against either steroid in a controlled study.
Can RAD140 be run alongside steroids such as testosterone or tren?
In the discussions, RAD140 is described most often alongside a testosterone base or prescribed testosterone replacement therapy (TRT), and less often added to tren, masteron (drostanolone), primobolan (methenolone) or nandrolone (NPP). The reasons given in those accounts are strength or a drier look, or covering the shutdown of endogenous testosterone that RAD140 causes. Nothing in the published record tests any of these combinations, so what follows is description, never instruction.
In those accounts the amounts involved differ from one description to the next, and the RAD140 doses named for the compound on its own are the only common reference. Some describe RAD140 as overshadowed once testosterone amounts are high, and some ask whether to lower the testosterone when RAD140 is added; one account describes lethargy with RAD140 alone that ended the attempt, followed by a second attempt on TRT. Questions about controlling oestrogen come up often, and a few accounts describe a prohormone or enclomiphene used as a base in place of testosterone.
Steroids found beside RAD140 in products and urine samples
Laboratory analyses have found anabolic-androgenic steroids alongside RAD140 both inside products and in human urine. The products are the commercially available supplements of the gynaecomastia case, which held undisclosed testosterone, oestradiol and growth hormone beside the SARMs detected in them; content fails in the other direction too, since the Therapeutic Goods Administration (TGA), Australia’s medicines regulator, found unapproved SARM products significantly under-dosed, so whether a product is legit RAD 140 turns on dose as well as on identity.
RAD140 came second. That is the telling detail of the urine data, which come from outside sport: specimens from a Swedish healthcare drug-testing laboratory were screened again by the doping control laboratory in Stockholm with methods accredited by the World Anti-Doping Agency (WADA), and SARMs turned up in a small share of the male specimens and in none of the female ones, as the chart below gives, with LGD-4033 (ligandrol), another nonsteroidal SARM, first, RAD140 second and ostarine (enobosarm) third.
[Figure 2. Steroids in SARM-positive Swedish urine samples. Swedish healthcare urine samples were re-analysed with WADA-accredited screening in Stockholm. Twenty of 542 male samples and none of 100 female samples held SARMs, and steroids were identified in 40% of the SARM-positive samples.]
The positives were rarely single. More than half of the SARM-positive samples contained two or more SARMs, anabolic-androgenic steroids were identified in a substantial share of the samples containing SARMs, as the chart shows, and many samples showed testosterone/epitestosterone ratios indicative of testosterone administration, the ratio that serves as the screening measure flagging administered testosterone.
Content, then, is the variable at issue, and the identity and purity of material matter more than the name on a label. The RAD-140 for sale here for laboratory research carries batch and purity data for each lot, as does every compound in the UK SARMs shop.
Does RAD140 show up on a steroid test?
[Figure 3. How laboratories detect RAD140 by its ions. Anti-doping laboratories work from synthesised reference material to diagnostic fragments at m/z 223 and 205, then to urinary metabolites and routine doping control, with a urine window of several weeks. Each step is specific to the compound, not to steroids.]
Anti-doping laboratories detect this compound with methods built for it rather than with a steroid screen as such. In a RAD 140 drug test for doping control, those methods couple chromatography to mass spectrometry and aim at both the intact drug and its diagnostic urinary metabolites, the breakdown products excreted in urine; for RAD140 the characterisation work proposed diagnostic product ions at m/z 223 and 205 under electrospray ionisation and at m/z 421 and 349 under electron ionisation, established so that detection could be implemented in routine gas- and liquid-chromatographic doping control.
Detection windows for the class are long, since most SARMs can be detected in urine for several weeks, and hair or nail testing can complement urinalysis without overruling it, because a negative result in those matrices cannot exclude administration of the detected drug. Whether the compound appears on a given panel depends on what that panel targets: the Swedish healthcare samples showed SARMs only once they had been re-analysed with WADA-accredited methods, and that gap between panels decides the outcome of a SARMs drug test, since a panel finds only the compounds it includes.
In the sport rulebook RAD140 sits on the same side as the steroids: SARMs joined the WADA Prohibited List in 2008 under other anabolic agents, prohibited at all times.
Open questions in the RAD140 and steroid comparison
The chemistry and receptor evidence that RAD 140 is not a steroid is preclinical and cellular: binding and anabolic characterisation come from rat and monkey models, the androgenic activity and the binding-mode comparison from yeast and prostate carcinoma cell assays with in silico modelling.
The harm data are thinner still, single published cases, two of which involved products containing several compounds at once, and in one of those the authors call the role of RAD-140 speculative. The product-content finding comes from the Australian market alone, the urine finding from one Swedish laboratory’s samples re-analysed with anti-doping methods, and no measured ranking exists between RAD140 and oxandrolone, trenbolone, methandienone or a prohormone, because none of the studies this article draws on sets them against one another in the same participants.
The comparisons most often drawn therefore rest on descriptions outside the trials alone: how RAD140’s strength, size, dryness and vascularity stand against oxandrolone; the aggression likened to trenbolone; the difference in blood lipids between oxandrolone and RAD140; the lethargy; and how RAD140 is described beside trenbolone or methandienone. None of these comparisons has been measured in any published study among this article’s sources.
What the RAD140 evidence rests on
Claim
Evidence
Model or sample
Source
Nonsteroidal structure
Mass-spectrometric characterisation of synthesised reference material
Laboratory chemistry
Binds the androgen receptor; anabolic
Preclinical characterisation; Ki 7 nM vs 29 nM for the comparator
Rats and monkeys
Still androgenic
Yeast androgen screen, prostate cell reporter assay, in silico modelling
Cells and computer model
Liver injury
Single case report
1 man, 24 years old
Testosterone suppression
Single case report with product analysis
1 man, 40 years old; products held hidden hormones
Splenic rupture
Single case report; role called speculative
1 man, 54 years old; also MK-677
Steroids taken alongside RAD140
Re-analysis with WADA-accredited methods
542 male and 100 female healthcare samples, one Swedish laboratory
Under-dosed products
Regulatory testing
Australian market
Measured ranking against oxandrolone, trenbolone, methandienone
None
No study among the sources
–
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
What does the label 'SARM' tell you about whether a compound is a steroid?
Little, since the class includes steroidal members such as YK-11 ✓
That it lacks a steroid skeleton, as the term means nonsteroidal
That it is a steroid, since it acts on the androgen receptor
That it is a prohormone, converted by enzymes into a steroid
A doping-control review lists RAD-140 among the nonsteroidal SARMs but names MK-0773 and YK-11 as SARMs that keep a steroid skeleton, so the label alone settles little.
What did the yeast and prostate-cell bioassays show about RAD-140's androgenic activity?
Activity in both, markedly stronger in the yeast screen
Activity in both, markedly stronger in the prostate cells ✓
Activity in the yeast screen alone, none in the prostate cells
No androgenic activity in either of the two assays
RAD-140 was androgenic in both assays, and more strongly so in prostate carcinoma cells, so its selectivity is a matter of degree rather than of kind.
What limits the one published case linking RAD-140 products to suppressed testosterone signalling?
The man had a suspected pre-existing pituitary gland malformation
Analysis of the products found no RAD-140 in any of them
The products also held undisclosed testosterone and oestradiol ✓
The suppression persisted for years after exposure had ended
The supplements also contained hidden testosterone, oestradiol and growth hormone, so the suppression cannot be pinned on RAD-140 alone, and it resolved once exposure ended.
On what grounds were SARMs such as RAD140 added to the WADA Prohibited List in 2008?
Their four-ring steroid skeleton, like testosterone's
Their enzymatic conversion into active steroids
Their approved medical use as prescription drugs
Their anabolic effects on skeletal muscle and bone ✓
SARMs were listed for their anabolic effects on muscle and bone, although none had full clinical approval, so in sport RAD140 is classed by effect rather than by chemical core.
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
RAD 140 and TRT have never been studied together: the only human trial was in women with breast cancer, and a case report records suppressed testosterone.
RAD 140 vs LGD has never been compared in a trial: LGD-4033’s trial lowered testosterone and HDL, while RAD140’s raised liver enzymes in most participants.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
Is RAD 140 a steroid? How it differs from Anavar and tren
By Laura Walker, PhD · Reviewed by Elizabeth Hyams
Published · Updated · 17 min read
Why RAD 140 counts as a SARM and not a steroid
Is RAD 140 a steroid? No. It is a selective androgen receptor modulator (SARM), a nonsteroidal compound built on a chemical core other than the four-ring steroid skeleton. It shares its target with testosterone and the steroids derived from it: the compound, also called testolone, switches on the androgen receptor, the protein androgens act through inside cells.
Chemistry and anti-doping papers agree on the grouping. They place the compound with the nonsteroidal SARMs, built on a core other than the steroid skeleton, and apart from the anabolic-androgenic steroids, the synthetic derivatives of testosterone. A different structure does not mean milder harm: published cases describe drug-induced liver injury and suppression of endogenous testosterone signalling after exposure to products containing RAD 140. The comparisons drawn with Anavar (oxandrolone) and tren (trenbolone), both members of the steroid class, one orally active and the other injectable, rest on descriptions outside the published trials rather than on any trial.
Where does the compound come from? The SARM RAD140 was designed as a potent, orally bioavailable drug candidate in a medicinal chemistry programme that characterised the SARM testolone in preclinical models of anabolic action, the building of skeletal muscle and bone tissue. It entered clinical development under the name vosilasarm, and no regulator has granted it full clinical approval: the record from the discovery programme to vosilasarm is that of a research compound, not of an approved medicine.
This article sets out what the compound is chemically and how it acts at the receptor compared with anabolic-androgenic steroids and with prohormones, precursors that enzymes convert into active steroids; what the published cases and laboratory analyses recorded; and how the compound is described beside Anavar, trenbolone and methandienone (dbol), an orally active 17-alpha-alkylated steroid. Dose plans and UK law have their own pages.
How RAD140’s structure differs from a steroid’s
RAD-140 rests on a 5-phenyloxadiazole nucleus, a ring system unrelated to the four-ring skeleton of testosterone and its derivatives, and that is what places it among the non-steroidal SARMs. Its discovery paper says the same in its own words (a nonsteroidal selective androgen receptor modulator), and the two descriptions agree because of the structural distance from testosterone.
The same structure answers whether RAD 140 is natural. It is synthetic, designed and made in a medicinal chemistry programme, and anti-doping chemists later prepared reference material for it by established synthetic routes so that they could characterise its mass-spectrometric behaviour; its origin lies in the laboratory, not in a plant or in animal tissue.
Steroidal and nonsteroidal SARMs named in sources
The SARM class is chemically mixed, so the label alone decides little: what unites selective androgen receptor modulators is the receptor pharmacology they share despite that variety. A doping-control review lists RAD-140 among the nonsteroidal representatives and names MK-0773 and YK-11 as steroidal SARMs, members of the class that keep a steroid skeleton; calling a compound a SARM therefore says nothing about its skeleton, and on that division RAD-140 falls on the nonsteroidal side.
The grouping has shaped how the compound’s breakdown has been studied. One study examined RAD-140 alongside six other non-steroidal SARMs in equine liver microsomes, and for RAD-140 it identified four metabolites, the compounds a drug is broken down into.
How do prohormones differ from SARMs like RAD140?
In the comparison of SARMs vs prohormones, the first difference is the route: a prohormone becomes an active steroid only after enzymes convert it in the body, while RAD140 needs no such step. The second is the range of tissues acted on. The differences, and the qualification that narrows them, run along five points, each as it is commonly described:
How RAD140 acts on the androgen receptor compared with steroids
RAD140 acts on the same androgen receptor as testosterone and the anabolic-androgenic steroids, and in preclinical work it is anabolic: its discovery paper settled whether RAD 140 is anabolic by characterising it in preclinical models of anabolic androgen action in rats and monkeys. Receptor binding was reported there as a Ki, or binding constant, lower than the comparator’s, as the chart below shows, and a lower Ki means tighter binding, which is what a nonsteroidal compound acting at the receptor steroids use would be expected to show.
So the difference between SARMs and steroids lies not in the receptor but in the balance between two effects. A forensic review describes SARMs as presenting anabolic properties identical to those of anabolic-androgenic steroids with markedly reduced androgenic effects, and the published liver case describes RAD-140 as potently anabolic on bone and muscle tissue with little androgenic effect. That balance, followed through the receptor, is what separates the two classes.
Selectivity is not absence, and tissue selectivity left RAD-140 with androgenic activity in both a yeast androgen screen, a reporter assay in yeast cells that detects androgenic compounds, and a reporter gene assay in prostate carcinoma cells, markedly stronger in the prostate cells than in the yeast, and molecular modelling of the androgen receptor ligand binding domain found only slight differences in binding mode between RAD-140 and two other non-steroidal SARMs. On these data selectivity is a matter of degree rather than of kind.
The nonsteroidal core did not spare the liver: the best-documented harm in the published cases is RAD 140 liver injury, with a gynaecomastia case and a splenic rupture beside it, all set out in their own articles.
How much does RAD140 shut down testosterone compared with steroids?
One published case of exposure to products containing RAD-140 measured the hormone axis, and in it endogenous testosterone signalling was shut down: a biochemical hypogonadotropic hypogonadism, low testosterone together with low pituitary gonadotropin output. The same products held undisclosed steroid hormones, so the suppression cannot be apportioned between RAD-140 and those hormones.
The details set that limit. A 40-year-old man developed bilateral gynaecomastia, enlargement of male breast tissue, alongside the biochemical picture after six months of exposure to three commercially available supplements; analysis found RAD-140, MK-677 and cardarine (a PPAR-delta agonist), and in all three undisclosed testosterone, growth hormone and oestradiol (the principal oestrogen), while liquid chromatography-mass spectrometry, the separation and mass-measurement method used for steroid analysis, detected an unidentified compound coeluting close to the testosterone peak.
Once exposure ended, the symptoms resolved fully and the hypogonadotropic hypogonadism normalised. What the case records is suppression produced by a mixture of a SARM and administered steroid hormones acting on one hypothalamic-pituitary-gonadal axis; to compare its degree with an anabolic-androgenic steroid’s would take RAD-140 administered alone with the hormone axis measured, a design absent from the studies this article draws on.
How does RAD140 compare with anavar for strength, gains and side effects?
Among the effects described outside the trials, the strength and size attributed to RAD140 beside oxandrolone divide sharply: in some accounts oxandrolone does clearly more over a comparable period, in others the two yield much the same strength, hardness and vascularity, with RAD140 said to be nearly as drying, and the descriptions leave open whether RAD140 matches oxandrolone for lean body mass as well as for strength.
Accounts outside the published studies make the blood lipids (the HDL and LDL cholesterol fractions measured in a blood panel) the sharpest divergence on side effects, describing them as worsening far more after exposure to oxandrolone than after RAD140, and oxandrolone as driving cholesterol and liver markers up; in descriptions beyond the trials RAD140’s advantage in side effects is itself questioned, so these competing accounts settle nothing that a measurement would.
Outside the trial record, suppression of endogenous hormones is the point of sharpest disagreement: oxandrolone on its own is said rarely to suppress endogenous testosterone completely, though other accounts question that at higher amounts, and beyond the trial data oxandrolone is placed above the SARM class in potency and below the injectable anabolic-androgenic steroids, an ordering that leaves RAD140 lower still on a rough scale of strength.
Outside the published trials, in descriptions concerning women, oxandrolone predominates and RAD140 appears in only a few; such descriptions come from RAD-140 Reddit and other online accounts, with no figures attached to any of them.
How does RAD140 compare with tren or dbol?
Outside the published trials, RAD140 is described as weaker than trenbolone or methandienone, both spoken of as the stronger agents, so a straight RAD 140 vs tren substitution is rarely the comparison drawn; where the two are compared directly, one account calls the effect on aggression tren-like while holding that it comes without trenbolone’s harsher effects, and other descriptions ask instead how RAD140 stands for strength alone against stanozolol (winstrol), another of the orally active anabolic-androgenic steroids.
In those accounts methandienone enters chiefly through aromatisation, the enzymatic conversion of an androgen into oestrogen: alone it is described as bringing quick fullness and weight that does not hold once exposure ends, and accounts outside the published studies record suspicion that material sold as RAD140 was in fact a prohormone or liquid methandienone.
On the pharmacology rather than the descriptions, RAD140 is generally held to be a different kind of compound from either of the two, not a weaker version of one. Non-steroidal and built to favour skeletal muscle and bone over prostate tissue, it is usually described as having milder androgenic and oestrogenic effects than either, while trenbolone is commonly described as strongly androgenic and non-aromatising and as acting on the progesterone receptor, and methandienone is generally held to convert to oestrogen and is widely linked with strain on liver tissue. The usual qualification stands: RAD140 still suppresses endogenous testosterone production, has been linked with drug-induced liver injury in published cases, and has never been set against either steroid in a controlled study.
Can RAD140 be run alongside steroids such as testosterone or tren?
In the discussions, RAD140 is described most often alongside a testosterone base or prescribed testosterone replacement therapy (TRT), and less often added to tren, masteron (drostanolone), primobolan (methenolone) or nandrolone (NPP). The reasons given in those accounts are strength or a drier look, or covering the shutdown of endogenous testosterone that RAD140 causes. Nothing in the published record tests any of these combinations, so what follows is description, never instruction.
In those accounts the amounts involved differ from one description to the next, and the RAD140 doses named for the compound on its own are the only common reference. Some describe RAD140 as overshadowed once testosterone amounts are high, and some ask whether to lower the testosterone when RAD140 is added; one account describes lethargy with RAD140 alone that ended the attempt, followed by a second attempt on TRT. Questions about controlling oestrogen come up often, and a few accounts describe a prohormone or enclomiphene used as a base in place of testosterone.
Steroids found beside RAD140 in products and urine samples
Laboratory analyses have found anabolic-androgenic steroids alongside RAD140 both inside products and in human urine. The products are the commercially available supplements of the gynaecomastia case, which held undisclosed testosterone, oestradiol and growth hormone beside the SARMs detected in them; content fails in the other direction too, since the Therapeutic Goods Administration (TGA), Australia’s medicines regulator, found unapproved SARM products significantly under-dosed, so whether a product is legit RAD 140 turns on dose as well as on identity.
RAD140 came second. That is the telling detail of the urine data, which come from outside sport: specimens from a Swedish healthcare drug-testing laboratory were screened again by the doping control laboratory in Stockholm with methods accredited by the World Anti-Doping Agency (WADA), and SARMs turned up in a small share of the male specimens and in none of the female ones, as the chart below gives, with LGD-4033 (ligandrol), another nonsteroidal SARM, first, RAD140 second and ostarine (enobosarm) third.
The positives were rarely single. More than half of the SARM-positive samples contained two or more SARMs, anabolic-androgenic steroids were identified in a substantial share of the samples containing SARMs, as the chart shows, and many samples showed testosterone/epitestosterone ratios indicative of testosterone administration, the ratio that serves as the screening measure flagging administered testosterone.
Content, then, is the variable at issue, and the identity and purity of material matter more than the name on a label. The RAD-140 for sale here for laboratory research carries batch and purity data for each lot, as does every compound in the UK SARMs shop.
Does RAD140 show up on a steroid test?
Anti-doping laboratories detect this compound with methods built for it rather than with a steroid screen as such. In a RAD 140 drug test for doping control, those methods couple chromatography to mass spectrometry and aim at both the intact drug and its diagnostic urinary metabolites, the breakdown products excreted in urine; for RAD140 the characterisation work proposed diagnostic product ions at m/z 223 and 205 under electrospray ionisation and at m/z 421 and 349 under electron ionisation, established so that detection could be implemented in routine gas- and liquid-chromatographic doping control.
Detection windows for the class are long, since most SARMs can be detected in urine for several weeks, and hair or nail testing can complement urinalysis without overruling it, because a negative result in those matrices cannot exclude administration of the detected drug. Whether the compound appears on a given panel depends on what that panel targets: the Swedish healthcare samples showed SARMs only once they had been re-analysed with WADA-accredited methods, and that gap between panels decides the outcome of a SARMs drug test, since a panel finds only the compounds it includes.
In the sport rulebook RAD140 sits on the same side as the steroids: SARMs joined the WADA Prohibited List in 2008 under other anabolic agents, prohibited at all times.
Open questions in the RAD140 and steroid comparison
The chemistry and receptor evidence that RAD 140 is not a steroid is preclinical and cellular: binding and anabolic characterisation come from rat and monkey models, the androgenic activity and the binding-mode comparison from yeast and prostate carcinoma cell assays with in silico modelling.
The harm data are thinner still, single published cases, two of which involved products containing several compounds at once, and in one of those the authors call the role of RAD-140 speculative. The product-content finding comes from the Australian market alone, the urine finding from one Swedish laboratory’s samples re-analysed with anti-doping methods, and no measured ranking exists between RAD140 and oxandrolone, trenbolone, methandienone or a prohormone, because none of the studies this article draws on sets them against one another in the same participants.
The comparisons most often drawn therefore rest on descriptions outside the trials alone: how RAD140’s strength, size, dryness and vascularity stand against oxandrolone; the aggression likened to trenbolone; the difference in blood lipids between oxandrolone and RAD140; the lethargy; and how RAD140 is described beside trenbolone or methandienone. None of these comparisons has been measured in any published study among this article’s sources.
What the RAD140 evidence rests on
Check what you remember
4 questions on this article; the right answer is marked.
A doping-control review lists RAD-140 among the nonsteroidal SARMs but names MK-0773 and YK-11 as SARMs that keep a steroid skeleton, so the label alone settles little.
RAD-140 was androgenic in both assays, and more strongly so in prostate carcinoma cells, so its selectivity is a matter of degree rather than of kind.
The supplements also contained hidden testosterone, oestradiol and growth hormone, so the suppression cannot be pinned on RAD-140 alone, and it resolved once exposure ended.
SARMs were listed for their anabolic effects on muscle and bone, although none had full clinical approval, so in sport RAD140 is classed by effect rather than by chemical core.
Laura Walker, PhD · Newcastle University
Postdoctoral Research Associate
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Elizabeth Hyams · Imperial College London · Last reviewed
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Related Posts
Ostarine with cardarine: what is known and how they differ
The ostarine cardarine stack has one human record, a case of liver injury with rhabdomyolysis, and pairs a SARM with a PPAR-delta agonist.
Ostarine vs LGD: trial data, RAD140, MK-677 and anavar
Ostarine vs LGD has never been tested in one trial: separate placebo trials each recorded over 1 kg more lean mass, with lower testosterone and HDL.
RAD 140 and TRT: the evidence on a testosterone base
RAD 140 and TRT have never been studied together: the only human trial was in women with breast cancer, and a case report records suppressed testosterone.
RAD 140 vs LGD: trial data, ostarine, YK-11 and MK-677
RAD 140 vs LGD has never been compared in a trial: LGD-4033’s trial lowered testosterone and HDL, while RAD140’s raised liver enzymes in most participants.